Effect of antidepressants on cognitive and psychomotor function: The lack of effect of reboxetine

Human Psychopharmacology

Volumn 13, Issue SUPPL. 1, 1998, Pages

  Hindmarch, I ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Amitriptyline; Antidepressant; Cognitive function; Psychomotor performance; Reboxetine

Indexed keywords

ALCOHOL; AMITRIPTYLINE; NORADRENALIN UPTAKE INHIBITOR; REBOXETINE;

ALCOHOL CONSUMPTION; BEHAVIOR DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; RANDOMIZED CONTROLLED TRIAL;

EID: 0031911674     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1077(199802)13:1+3.0.CO;2-V     Document Type: Conference Paper

References (29)

1. Alvarez, F. J. and Carmen del Rio, M. (1994). Drugs and driving. Lancet, 344, 282.
2. Berzewski, H., Van Moffaen, M. and Gagiano, C. A. (1997). Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. European Neuropsychopharmcology, 7 (Suppl. 1), S37-S47.
3. Byrne, D. G. (1976). Choice reaction time in depressive states. British Journal of Social and Clinical Psychology, 15, 149-156.
4. Cohen, R. M. and Weingartner, H. (1982). Effort and cognition in depression. Archives of General Psychiatry, 39, 593-597.
5. Crome, P. (1993). The toxicity of drugs used for suicide. Acta Psychiatrica Scandinavica, 371, 33-37.
6. Currie, D. J., Hashemi, K., Fothergill, J., Findlay, A., Harris, A. and Hindmarch, I. (1995). Antidepressant and benzodiazepine use and the risk of accidents. Occupational Medicine, 45, 323-325.
7. Damliyi, N. F. and Ferguson, J. M. (1988). Paradoxical worsening of depressive symptomatology caused by antidepressants. Journal of Clinical Psychopharmacology, 8, 347-349.
8. De Gier, J. J. (1993). Driving Licenses and Known Use of Licit and Illicit Drugs. Institute for Human Psychopharmacology, University of Limburg.
9. De Gier, J. J. (1995). Drugs Other Than Alcohol and Driving in the European Union. Report to the Directorate General for Transport of the Commission of the European Communities. IHP, University of Limburg.
10. Drummer, O. H., Kotsos, A. and McIntrye, I. M. (1993). A class-independent drug screen in forensic toxicology using a photodiode array detector. Journal of Analytic Toxicology, 17, 225-229.
11. Hale, A. S. and Pinninti, N. R. (1995). Critical flicker fusion threshold and anticholinergic effects of chronic antidepressant treatment in remitted depressives. Journal of Psychopharmacology, 9, 216-224.
12. Hanks, G. W. (1984). The effect of amitriptyline and nomifensine on critical flicker fusion threshold in an elderly patient population. In Nomifensine: a Pharmacological and Clinical Profile, RSM ICSS No. 70, Rees, L. W. and Priest, R. G. (eds), pp. 95-97, OUP, Oxford.
13. Henry, J. A. (1992). Toxicity of antidepressants. International Clinical Psychopharmacology, 6, 22-27.
14. Hindmarch, I. (1975). A 1-4-benzodiazepine, temazepam (K 3917) its effect on some psychological parameters of sleep and behaviour. Arzneimittel. Forschung (Drug Research), 25, 1836-1839.
15. Hindmarch, I. (1980). Psychomotor function and psychoactive drugs. British Journal of Clinical Pharmacology, 10, 189-209.
16. Hindmarch, I. (1982). Critical flicker fusion frequency (CFFF): The effects of psychotropic compounds. Pharmacopsychiatry, 15, 44-48.
17. Hindmarch, I. (1988). A pharmacological profile of fluoxetine and other antidepressants on aspects of skilled performance and car handling ability. British Journal of Psychiatry, 153, 99-104.
18. Hindmarch, I. and Kerr, J. S. (1994). Hidden costs ignored. (Letter). British Medical Journal, 309, 1083.
19. Kerr, J. S. and Hindmarch, I. (1996). Citalopram and other antidepressants: comparative effect on cognitive function and psychomotor performance. Journal of Serotonin Research, 3, 123-129.
20. Kerr, J. S., Powell, J. and Hindmarch, I. (1996). The effects of reboxetine and amitriptyline, with and without alcohol on cognitive function and psychomotor performance. British Journal of Clinical Pharmacology, 42, 239-241.
21. Lord, S. R., Anstey, K. J., Williams, P. and Ward, J. A. (1995). Psychoactive medication use, sensorimotor function and falls in older women. British Journal of Clinical Pharmacology, 39, 227-234.
22. MORI (1995). Attitudes Towards Depression MORI/8624. MORI/The Royal College of Psychiatrists, London.
23. Oster, G., Husc, D. M., Adams, S. F., Imbimbo, J. and Russell, M. W. (1990). Benzodiazepine tranquillisers and the risk of accidental injury. American Journal of Public Health, 80, 1-11.
24. Ray, W. A., Griffin, M. R. and Downey, W. (1989). Benzodiazepines of long and short elimination half-life and the risk of hip fracture. Journal of the American Medical Association, 262, 3303-3307.
25. Ray, W. A., Fought, R. L. and Decker, M. D. (1992). Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers. American Journal of Epidemiology, 136, 873-883.
26. Riva, M., Brunello, N., Rovescalli, A. C., Galimberti, R., Carfagna, N., Carminati, P., Pozzi, O., Ricciardi, S., Roncucci, R., Rossi, A. and Racagni, G. (1989). Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system: behavioural and biochemical studies. Journal of Drug Development, 1, 243-253.
27. Sobel, K. G. and McCart, G. M. (1983). Drug use and accidental falls in an intermediate care facility. Drug Intelligence and Clinical Pharmacology, 17, 539-542.
28. Widlocher, D. (1983a). Psychomotor retardation: clinical, theoretical and psychometric aspects. Psychiatric Clinics of North America, 6, 27-39.
29. Widlocher, D. (1983b). La Ralentissement Depressif. Presses Universitaires de France, Paris.